文献速递胸部肿瘤

非小细胞肺癌术后异体输血与复发风险的倾向评分分析

The association of non-small cell lung cancer recurrence with allogenic blood transfusion after surgical resection: A propensity score analysis of 1,803 patients.
PubMed 文献 · Eur J Cancer · 2020-10-08

本研究基于1803例I-III期非小细胞肺癌手术患者,采用Cox回归和IPTW平衡混杂因素,分析术后7天内因血红蛋白低于8.0 g/dL接受异体输血与复发的关系。209例(11.6%)接受输血,中位随访42个月,输血者早期复发风险(IPTW调整HR 1.81,95%CI 1.59-2.06,P<0.001)和全因死亡风险(IPTW调整HR 2.38,95%CI 1.97-2.87,P<0.001)显著增高,且输血量与复发/死亡呈非线性剂量反应。结论支持减少输血暴露的临床策略。

要点

  • 术后输血者早期复发风险增加,IPTW调整HR 1.81(95%CI 1.59-2.06)。
  • 术后输血者全因死亡风险增加,IPTW调整HR 2.38(95%CI 1.97-2.87)。
  • 输血量与复发和死亡呈非线性剂量反应关系。

核心结论

  • NSCLC术后接受异体输血与更高的疾病复发和早期死亡风险相关,支持采用减少输血暴露的临床策略。

研究设计与样本

  • 回顾性队列研究,纳入1803例I-III期NSCLC手术患者,采用Cox回归和IPTW平衡混杂因素,并以限制性立方样条分析剂量反应。

主要发现

  • 1803例中209例(11.6%)接受输血,中位随访42个月(四分位距24.9-71.9)。
  • 输血者早期复发风险更高,IPTW调整HR 1.81(95%CI 1.59-2.06,P<0.001)。
  • 输血者全因死亡风险更高,IPTW调整HR 2.38(95%CI 1.97-2.87,P<0.001)。
  • 输血量与复发或死亡之间存在非线性剂量反应关系。

临床怎么用

  • 对NSCLC术后患者应审慎评估输血指征,采用策略减少不必要的异体输血暴露。

局限性

  • 原文指出既往研究样本量不足且未充分测量重要混杂因素,本研究虽用稳健统计和加权协变量,仍需进一步研究确定指导循证实践的基准。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Conflicting evidence underlies the controversial role of allogenic blood transfusion in recurrence of non-small cell lung cancer (NSCLC). Insufficient sample size and failure to measure effects of important confounders in previous studies contribute to the conflicting findings. To overcome these limitations, we applied robust statistics and weighted covariates in a large study cohort. METHODS: Cox regression analyses were used to estimate the recurrence and survival in patients with NSCLC disease stages I through III who were transfused for a haemoglobin level less than 8.0 g/dL within seven days after surgical resection. Inverse probability of treatment weighting (IPTW) was used to balance covariates in the sequential cohort of patients receiving an incremental amount of blood. We applied restricted cubic spline functions to characterise dose-response effects of transfusion amount on recurrence and mortality. RESULTS: A total of 209 (11.6%) of 1803 patients received transfusions. Over a median of 42 months after surgery (interquartile range 24.9-71.9), patients who received blood had a greater risk of early recurrence (IPTW-adjusted HR: 1.81, 95% CI: 1.59-2.06, P < 0.001) and all-cause mortality (IPTW-adjusted hazard ratio, HR: 2.38, 95% CI: 1.97-2.87, P < 0.001). A non-linear dose-response occurred between transfusion amount and recurrence or mortality. CONCLUSIONS: The greater risk of disease recurrence and early mortality after surgical resection in NSCLC patients who receive blood transfusion supports use of clinical strategies to reduce exposure. Further studies are needed to identify benchmarks to guide evidence-based practices.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Tai YH, Wu HL, Mandell MS, et al. The association of non-small cell lung cancer recurrence with allogenic blood transfusion after surgical resection: A propensity score analysis of 1,803 patients. Eur J Cancer. 2020. PMID: 33039813. doi:10.1016/j.ejca.2020.09.004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。